Evidence map›Paper›PMID 25118275›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

PIP5K1α inhibition as a therapeutic strategy for prostate cancer.

Justin M Drake, Jiaoti Huang

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Justin M DrakeDepartment of Microbiology, Immunology, and Molecular Genetics, jdrake@mednet.ucla.edu jiaotihuang@mednet.ucla.edu.
Jiaoti HuangJonsson Comprehensive Cancer Center, and Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095 jdrake@mednet.ucla.edu jiaotihuang@mednet.ucla.edu.

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
A novel strategy to identify prostate cancer biomarkers for patient managementR01CA172603 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, JIAOTI · 2013 to 2017
$1.6M
Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the ProstateR01CA158627 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARKS, LEONARD STEPHEN · 2011 to 2013
$1.4M
NCI NIH HHS R01 CA158627NCI NIH HHS R01 CA172603
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDiketopiperazinesHumansIndolesIsoquinolinesMalePhosphotransferases (Alcohol Group Acceptor)Prostatic NeoplasmsTetrahydroisoquinolines1,2,3,4-tetrahydroisoquinoline1-phosphatidylinositol-4-phosphate 5-kinaseDiketopiperazinesIndolesISA-2011BIsoquinolinesPhosphotransferases (Alcohol Group Acceptor)Tetrahydroisoquinolines

Identifiers

PMID25118275
PMCPMC4156720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.